[1]王立强,雷春花,邱飞,等.萘甲酰胺衍生物TW918的合成及体外活性考察[J].华侨大学学报(自然科学版),2015,36(3):309-313.[doi:10.11830/ISSN.1000-5013.2015.03.0309]
　WANG Li-qiang,LEI Chun-hua,QIU Fei,et al.Synthesis and In Vitro Activity of Naphthamide Derivatives TW918[J].Journal of Huaqiao University(Natural Science),2015,36(3):309-313.[doi:10.11830/ISSN.1000-5013.2015.03.0309]
点击复制

萘甲酰胺衍生物TW918的合成及体外活性考察()
分享到：

《华侨大学学报（自然科学版）》[ISSN:1000-5013/CN:35-1079/N]

卷:
第36卷
期数:
2015年第3期
页码:
309-313
栏目:
出版日期:
2015-05-20

文章信息/Info

Title:
Synthesis and In Vitro Activity of Naphthamide Derivatives TW918
文章编号:
1000-5013(2015)03-0309-05
作者:
王立强;  雷春花;  邱飞;  杨会勇
华侨大学 生物医学学院, 福建 泉州 362021
Author(s):
WANG Li-qiang;  LEI Chun-hua;  QIU Fei;  YANG Hui-yong
School of Biomedical Science, Huaqiao University, Quanzhou 362021, China
关键词:
萘甲酰胺衍生物;  受体酪氨酸激酶;  抗肿瘤活性;  分子对接
Keywords:
naphthamide derivatives;  receptor tyrosine kinase;  anti-tumor activity;  molecular docking
分类号:
R916
DOI:
10.11830/ISSN.1000-5013.2015.03.0309
文献标志码:
A
摘要:
合成一系列萘甲酰胺衍生物,初步筛选出先导化合物TW918,测定其对肿瘤细胞的活性影响,考察其与激酶分子EGFR的结合性及对EGFR蛋白表达的影响.TW918结构经1H-NMR,13C-NMR和HR-MS表征确证.实验结果表明:TW918对四种肿瘤细胞均有一定的抑制活性,但对正常细胞的影响较小;分子对接显示TW918能以母核喹啉为头,深入占据到EGFR的活性口袋中,并与活性残基形成氢键,其最低自由结合能为-46.1 kJ·mol-1;TW918能以剂量依赖性方式明显抑制四种肿瘤细胞中EGFR蛋白的表达.
Abstract:
To synthesize a series of naphthamide derivatives and screen out one lead compound TW918, this paper studys its anti-tumor activity in vitro, and investigats its ability to bind with kinase and the effect on the expression of EGFR protein. 1H-NMR, 13C-NMR and HR-MS confirmed the structure of TW918. The results of MTT assay showed that TW918 had certain inhibitory effects against four types of tumor cells, but had less effects on normal cells. Molecular docking revealed that TW918 could make use of the quinoline as head to occupy the activity pocket of EGFR deeply, and form hydrogen bonds with the active residues of EGFR around it, whose lowest free binding energy was -46.1 kJ·mol-1. Western Blot demonstrated that TW918 could inhibit the expression of EGFR in all four types of tumor cells in a dose-dependent manner significantly.

参考文献/References:

[1] CHEN Xiao-guang,ZHANG Yi.Recent advance in the study of novel anti-tumor targets and drugs: Aurora kinase and Pin1[J].Acta Pharm Sin,2009,44(3):264-269.
[2] 李娟,李延团,李晓明,等.分子靶向抗肿瘤药物研究进展[J].生物技术通讯,2009,20(3):411-416.
[3] WEI L,MALHOTRA S V.Recent development of cyclic amide(pyridone/lactam)moiety containing heterocycles as protein kinase inhibitors[J].Curr Med Chem,2010,17(3):234-253.
[4] YOSHIMURA N,KUDOH S,KIMURA T,et al.EKB-569, a new irreversible epidermal growth factor receptor tyrosine kinase inhibitor, with clinical activity in patients with non-small cell lung cancer with acquired resistance to gefitinib[J].Lung Cancer,2006,51(3):363-368.
[5] 姜梦,刘丹,兰帅鹏.喹啉类蛋白酪氨酸激酶抑制剂的研究进展[J].化学试剂,2013,35(4):333-336.
[6] MOON D O,KIM M O,HEO M S,et al.Gefitinib induces apoptosis and decreases telomerase activity in MDA-MB-231 human breast cancer cells[J].Arch Pharm Res,2009,32(10):1351-1360.
[7] COSCONATIL S,FORLI A,PERRYMAN A L,et al.Virtual screening with AutoDock: Theory and practice[J].Expert Opinion on Drug Discovery,2010,5(6):597-607.
[8] CARMI C,CAVAZZONI A,VEZZOSI S,et al.Novel irreversible epidermal growth factor receptor inhibitors by chemical modulation of the cysteine-trap portion[J].Journal of Medicinal Chemistry,2010,53(5):2038-2050.
[9] 唐健红,曾庆友.阿魏酸异辛酯的绿色合成[J].华侨大学学报:自然科学版,2011,32(5):551-553.
[10] NIE Jian-yun,LIU Xin,JIN Cong-guo,et al.The effect of histone deacetylase inhibitors on cell cycle of breast cancer cell line MCF-7[J].Clinical Medicine of China,2009,25(12):1238-1240.

备注/Memo

备注/Memo:
收稿日期: 2015-02-09
通信作者: 王立强(1970-),男,教授,博士,主要从事药剂学和新药开发的研究.E-mail:wlq1599@163.com.
基金项目: 福建省自然科学基金资助项目(2010J01208); 福建省泉州市科技计划重点项目(2013Z35)
更新日期/Last Update: 2015-05-20